Good afternoon :)
Switch to
Place Order

Bal Pharma Ltd

BALPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹147 cr, stock is ranked 1,735
High RiskStock is 4.28x as volatile as Nifty
104.754.95 (+4.96%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹147 cr, stock is ranked 1,735
High RiskStock is 4.28x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
31.14
PB RatioPB Ratio
3.26
Dividend YieldDiv. Yield
0.96%
Sector PESector PE
40.14
Sector PBSector PB
5.78
Sector Div YldSctr Div Yld
0.62%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bal Pharma Limited is engaged in the manufacture and sale of pharmaceutical products. The Company’s business comprises of Active Pharmaceutical Ingredients (API), Finished Formulations, Ayurvedic, Research and Development.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

2018201920202021213.21226.02172.93251.672.803.80-12.224.75
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 2.39%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Reply to Clarification- Financial results 
Announced OnJul 13, 2021

The Exchange had sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is enclosed. | Download

The Exchange had sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is enclosed. | Download

Related Party Transactions 
Announced OnJul 12, 2021

Bal Pharma Limited has informed the Exchange about Disclosure of related Party Transactions for the financial year ended 31.03.2021. | Download

Bal Pharma Limited has informed the Exchange about Disclosure of related Party Transactions for the financial year ended 31.03.2021. | Download

Cash Dividend 
Ex. DateSep 17, 2019

Final • Div/Share: ₹ 1

See all events